Clinical Trials
9
Active:1
Completed:0
Trial Phases
3 Phases
Phase 1:7
Phase 2:1
Phase 3:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (9 trials with phase data)• Click on a phase to view related trials
Phase 1
7 (77.8%)Phase 2
1 (11.1%)Phase 3
1 (11.1%)A Study of SC0062 Capsule for the Treatment of IgA Nephropathy with Proteinuria
Phase 3
Recruiting
- Conditions
- IgA Nephropathy (IgAN)
- Interventions
- Drug: SC0062 strength 10mgDrug: Placebo matched to SC0062
- First Posted Date
- 2025-02-11
- Last Posted Date
- 2025-02-17
- Lead Sponsor
- Biocity Biopharmaceutics Co., Ltd.
- Target Recruit Count
- 360
- Registration Number
- NCT06819826
- Locations
- 🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, Yuexiu District, China
A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of BC3195 in Patients With Advanced or Metastatic Cancer
- First Posted Date
- 2024-08-12
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- Biocity Biopharmaceutics Co., Ltd.
- Target Recruit Count
- 148
- Registration Number
- NCT06548672
- Locations
- 🇺🇸
Case Western Reserve University, Cleveland, Ohio, United States
BC3402 in Combination With Durvalumab in Patients With Advanced Hepatocellular Carcinoma
Phase 1
Not yet recruiting
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Drug: BC3402 injection
- First Posted Date
- 2023-11-01
- Last Posted Date
- 2023-11-01
- Lead Sponsor
- Biocity Biopharmaceutics Co., Ltd.
- Target Recruit Count
- 83
- Registration Number
- NCT06111326
- Locations
- 🇨🇳
Zhongshan Hospital, Fudan University, Shanghai, China
SC0191 Plus Chemotherapy in Advanced Ovarian Canceradvanced Ovarian Cancer
Phase 1
Not yet recruiting
- Conditions
- Advanced Ovarian CancerSerous Ovarian Cancer
- Interventions
- First Posted Date
- 2023-09-26
- Last Posted Date
- 2023-09-26
- Lead Sponsor
- Biocity Biopharmaceutics Co., Ltd.
- Target Recruit Count
- 112
- Registration Number
- NCT06055348
Study of BC3402 in Combination With Azacitidine in Patients With MDS and CMML
Phase 1
Recruiting
- Conditions
- Chronic Myelomonocytic LeukemiaMyelodysplastic Syndromes
- Interventions
- First Posted Date
- 2023-08-01
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- Biocity Biopharmaceutics Co., Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT05970822
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, Tianjin, China
- Prev
- 1
- 2
- Next
News
No news found